Neurogene Inc.
NASDAQ:NGNEBiotechnology
+$0.76 today
- Market cap
- $365.67M
- Beta
- 2.04
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$4.42
Volume 0.25M
Average 0.16M
NGNE Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Neurogene Inc.NASDAQ: NGNE
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $4.05M a year earlier. Trailing-twelve-month stock-based compensation was $3.41M. Over 3 fiscal years it compounded at +124.6% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $852K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 14.18M USD
- Year-over-year change
- +70.5%
- 4-year CAGR
- +99.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.18M | +70.5% |
| FY2024 | 2024-12-31 | 8.32M | +486.7% |
| FY2023 | 2023-12-31 | 1.42M | +13.3% |
| FY2022 | 2022-12-31 | 1.25M | +39.7% |
| FY2021 | 2021-12-31 | 896K | — |
Stock-Based Compensation vs competitors
How NGNE compares with its peers on the latest reported figures
- NGNE's LTM Mar 2026 stock-based compensation of $3.41M is the smallest of the 8 companies compared; the peer median is $18.17M.
- Its year-over-year change of -69.9% is the lowest of 8, against a peer median of -8.6%.
- Over three fiscal years its annual growth of +124.6% compares with a peer median of +8.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.93M | +107.3% | -8.3% | 60.1% | |
| LTM Mar 2026 | $21.22M | -43.4% | -16.7% | 115.2% | |
| LTM Mar 2026 | $19.48M | -28.2% | +8.7% | 22.1% | |
| LTM Jun 2026 | $18.17M | +39.2% | -9.7% | 331.3% | |
| LTM Mar 2026 | $14.93M | +11.2% | +10.0% | — | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $11.19M | -19.1% | +89.6% | — |
| LTM Mar 2026 | $3.41M | -69.9% | +124.6% | — | |
| Peer median (excluding NGNE) | $18.17M | -8.6% | +8.7% | 60.1% | |
Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.52M) | (55.19M) | (36.32M) | (75.14M) | (90.35M) |
| Depreciation & Amortization | 947K | 3.2M | 3.3M | 3.25M | 3.09M |
| Deferred Income Tax | 0 | 0 | (105K) | 0 | 0 |
| Stock-Based Compensation | 896K | 1.25M | 1.42M | 8.32M | 14.18M |
| Change in Working Capital | 1.6M | (2.7M) | (4.02M) | (5.96M) | 268K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.98M | (3.61M) | 667K | (77K) | 627K |
| Other Working Capital | (1.39M) | 912K | (4.69M) | (5.88M) | (359K) |
| Other Non-Cash Items | 679K | 608K | (15.69M) | (1.07M) | (4.37M) |
| Operating Cash Flow | (46.4M) | (52.82M) | (51.42M) | (70.6M) | (77.17M) |
| Capital Expenditures | (18.37M) | (2.23M) | (321K) | (808K) | (1.18M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (198.45M) | (269.51M) |
| Sales of Investments | 0 | 0 | 5M | 74M | 284.7M |
| Other Investing Activities | 0 | 0 | 20.96M | 0 | 0 |
| Investing Cash Flow | (18.37M) | (2.23M) | 25.64M | (125.26M) | 14M |
| Debt Repayment | 0 | (1K) | (29K) | (52K) | (61K) |
| Common Stock Issued | 287K | 73K | 92.34M | 189.59M | 30.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 168K | (5.47M) | 0 |
| Financing Cash Flow | 51.06M | 66.53M | 92.48M | 184.07M | 30.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (13.71M) | 11.48M | 66.7M | (11.79M) | (32.74M) |
| Free Cash Flow | (64.77M) | (55.05M) | (51.74M) | (71.41M) | (78.36M) |
Neurogene Inc.
NASDAQ:NGNE
Intrinsic Alpha fair value
Locked
Current Price
$23.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.